While several studies, such as AWARD 10, Duration 8, and AGATE, have looked at the combined use of SGLT2 and GLP-1 receptor agonists in T2D patients, there have not yet been any studies specifically focused on the effectiveness of this combination for MASH treatment [147]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.